Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Hua Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2605-5697; OpenAlex author ID A5100403938. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2011: 1 paper · 2012: 6 papers · 2013: 4 papers · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 25

  1. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000002470↗
  2. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Co-author DOI 10.1016/j.xcrm.2024.101711↗
  3. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  4. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  5. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  6. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  7. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  8. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  9. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications. First author DOI 10.5858/arpa.2019-0477-ra↗
  10. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000914↗
  11. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Co-author DOI 10.1097/pas.0000000000000887↗
  12. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Co-author DOI 10.1097/pas.0000000000000738↗
  13. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Co-author DOI 10.1111/his.12732↗
  14. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000000491↗
  15. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2012.09.001↗
  16. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2013.07.030↗
  17. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal… Co-author DOI 10.1111/his.12234↗
  18. Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Last author DOI 10.1186/1475-2867-13-26↗
  19. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Co-author DOI 10.1002/cncr.26243↗
  20. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcom… Co-author DOI 10.1002/cncr.26651↗
  21. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Co-author DOI 10.1016/j.anndiagpath.2011.08.005↗
  22. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. First author DOI 10.1097/mpa.0b013e31823bcef2↗
  23. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreat… Co-author DOI 10.1097/pas.0b013e318240c1c0↗
  24. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/pas.0b013e31824104c5↗
  25. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. First author DOI 10.1002/cncr.25483↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huamin Wang · 19 shared papers, 2012–2026 · strength 1.78
  2. Matthew H. G. Katz · 20 shared papers, 2012–2026 · strength 1.63
  3. Anirban Maitra · 13 shared papers, 2015–2026 · strength 1.61
  4. Robert A. Wolff · 17 shared papers, 2012–2026 · strength 1.55
  5. Laura R. Prakash · 8 shared papers, 2015–2026 · strength 1.17
  6. Deyali Chatterjee · 10 shared papers, 2012–2024 · strength 0.97
  7. Jeffrey E. Lee · 15 shared papers, 2012–2023 · strength 0.93
  8. Dan Zhao · 5 shared papers, 2023–2026 · strength 0.91
  9. Michael P. Kim · 6 shared papers, 2021–2024 · strength 0.85
  10. Ching-Wei David Tzeng · 6 shared papers, 2021–2024 · strength 0.85
  11. Eugene Jon Koay · 5 shared papers, 2021–2024 · strength 0.74
  12. Naruhiko Ikoma · 4 shared papers, 2023–2024 · strength 0.63
  13. Gauri Rajani Varadhachary · 12 shared papers, 2012–2021 · strength 0.54
  14. Jason B. Fleming · 14 shared papers, 2011–2017 · strength 0.53
  15. Ignacio Ivan Wistuba · 3 shared papers, 2017–2024 · strength 0.38
  16. Yi Tat Tong · 2 shared papers, 2023–2024 · strength 0.33
  17. Mehran Taherian · 2 shared papers, 2023–2024 · strength 0.32
  18. Shaimaa Elzamly · 1 shared paper, 2026 · strength 0.28
  19. Mahmoud Yousef · 1 shared paper, 2026 · strength 0.28
  20. Peter W. T. Pisters · 8 shared papers, 2012–2015 · strength 0.24
  21. James L. Abbruzzese · 8 shared papers, 2011–2013 · strength 0.24
  22. Daowei Yang · 1 shared paper, 2024 · strength 0.21
  23. Yang Chen · 1 shared paper, 2024 · strength 0.21
  24. Xinlei Sun · 1 shared paper, 2024 · strength 0.21
  25. Huamin Wang · 2 shared papers, 2011–2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.